GSE235701 GSE261434 enasidenib 2 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE235701_GSE261434_enasidenib_2_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE235701_GSE261434_enasidenib_2_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE235701_GSE261434_enasidenib_2_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE235701_GSE261434_enasidenib_2_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

G protein signaling modulator 3

Gene

long intergenic non-protein coding RNA 511

Gene

LOXL1 antisense RNA 1

Gene

Myb/SANT DNA binding domain containing 7

Gene

TPTE pseudogene 1

Gene

tripartite motif containing 15

Gene

deleted in lymphocytic leukemia 2

Gene

ILF3 divergent transcript

Gene

TGF-beta induced TARBP2 interacting lncRNA

Gene

uncharacterized LOC124901321

  • Gene

    G protein signaling modulator 3


  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    LOXL1 antisense RNA 1


  • Gene

    Myb/SANT DNA binding domain containing 7


  • Gene

    TPTE pseudogene 1


  • Gene

    tripartite motif containing 15


  • Gene

    deleted in lymphocytic leukemia 2


  • Gene

    ILF3 divergent transcript


  • Gene

    TGF-beta induced TARBP2 interacting lncRNA


  • Gene

    uncharacterized LOC124901321

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.